

EAST

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	12355	((514/217.09,227.8,236.5,254.05,256,326,402,406) or (540/596) or (544/60,140,333,371) or (546/208) or (548/318.5,364.1,374.1)).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2006/01/23 10:45
L2	98135	thromb\$	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/01/23 10:45
L3	1922	1 and 2	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/01/23 10:45

Quick Search: within All Full-text Sources Go [◀ results list](#) [◀ previous](#) **3 of 596** [next ▶](#)**Journal Of Thrombosis And Haemostasis: JTH**

Volume 3, Issue 11, November 2005, Pages 2479-2486

ISSN: 1538-7933

MEDLINE®

BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study

Turpie, A G G; Fisher, W D; Bauer, K A; Kwong, L M; Irwin, M W; Kälebo, P; Misselwitz, F; Gent, M; OdiXa-Knee Study Group

HHS-General Hospital, Hamilton, Canada; e-mail turpiea@mcmaster.ca

This Document

- ▶ [Abstract-MEDLINE](#)

External Links

- [Abstract + References in Scopus](#)
- [Cited By in Scopus](#)

Actions

- [Cited By](#)
- [Save as Citation Alert](#)
- [E-mail Article](#)
- [Export Citation](#)

Abstract

BACKGROUND: BAY 59-7939, a novel, oral, direct **factor Xa** inhibitor, is in clinical development for the **prevention** of venous thromboembolism (VTE), a frequent complication following orthopaedic surgery. **METHODS:** In a multicenter, parallel-group, double-blind, double-dummy study, 621 patients undergoing elective total knee replacement were randomly assigned to oral BAY 59-7939 (2.5, 5, 10, 20, and 30 mg b.i.d., initiated 6-8 h postsurgery), or subcutaneous enoxaparin (30 mg b.i.d., initiated 12-24 h postsurgery). Treatment was continued until mandatory bilateral venography 5-9 days after surgery. The primary efficacy endpoint was a composite of any deep vein thrombosis (proximal and/or distal), confirmed non-fatal pulmonary embolism and all-cause mortality during treatment. The primary safety endpoint was major, postoperative bleeding during treatment. **RESULTS:** Of the 613 patients treated, 366 (59.7%) were evaluable for the primary efficacy analysis. The primary efficacy endpoint occurred in 31.7%, 40.4%, 23.3%, 35.1%, and 25.4% of patients receiving 2.5, 5, 10, 20 and 30 mg b.i.d. doses of BAY 59-7939, respectively (test for trend, $P = 0.29$), compared with 44.3% in the enoxaparin group. The frequency of major, postoperative bleeding increased with increasing doses of BAY 59-7939 (test for trend, $P = 0.0007$), with no significant difference between any dose group compared with enoxaparin. Bleeding endpoints were lower for the 2.5-10 mg b.i.d. doses compared with higher doses of BAY 59-7939. **CONCLUSIONS:** Oral administration of 2.5-10 mg b.i.d. of BAY 59-7939, early in the postoperative period, showed potential efficacy and an acceptable safety profile,

similar to enoxaparin, for the **prevention** of VTE in patients undergoing elective total knee replacement. [Journal Article; In English; England]

Citation Subset Indicators: Index Medicus

Journal Of Thrombosis And Haemostasis: JTH
Volume 3, Issue 11 , November 2005, Pages 2479-2486
ISSN: 1538-7933

This Document

- **Abstract-MEDLINE**

External Links



- [Abstract + References in Scopus](#)
- [Cited By in Scopus](#)

Actions

- [Cited By](#)
- [Save as Citation Alert](#)
- [E-mail Article](#)
- [Export Citation](#)

[◀ results list](#) [◀ previous](#) **3 of 596** [next ▶](#)

[Home](#) [Search](#) [Journals](#) [Books](#) [Abstract Databases](#) [My Profile](#) [Alerts](#)

[Help](#)

[Contact Us](#) | [Terms & Conditions](#) | [Privacy Policy](#)

Copyright © 2006 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.

Acta Chirurgica Hungarica

Volume 36, Issue 1-4 , 1997, Pages 356-358

ISSN: 0231-4614

MEDLINE®

Efficacy of prevention of thromboembolic complications with LMW-heparin in experiment

Szücs, G; Mikó, I; Ajzner, E; Póti, L; Szepesi, K; Furka, I

Department of Orthopaedic Surgery, University Medical School of Debrecen, Hungary

This Document► **Abstract-MEDLINE****External Links**

- [Abstract + References in Scopus](#)
- [Cited By in Scopus](#)

Actions

- [Cited By](#)
- [Save as Citation Alert](#)
- [E-mail Article](#)
- [Export Citation](#)

Abstract

The authors used an antithrombotic agent (Nadroparin Calcium) with anti-Xa effect in their experiments to prevent thromboembolic complications in the model of endoprosthetic replacement of the hip joint in mongrel dogs. 10 experimental animals (Group I.) were given doses of 100 A Xa ICU/kg/bwt of Nadroparin Calcium subcutaneously 4 hours prior to the operation and also once a day until the 3rd postoperative day; between the 4th and 10th postoperative days doses of 150 A Xa ICU/kg/bwt Nadroparin Calcium were given. The 10 control animals (Group II.) did not receive anticoagulant treatment. In both groups platelet count, activated partial thromboplastin times (APTT), prothrombin and fibrinogen levels as well as activated factor X inhibition (F Xa) were measured prior to surgery and also until the 14th postoperative day. No changes in APTT and prothrombin levels were detected during the experiment, however platelet count and fibrinogen levels as well as the extent of F Xa inhibition showed significant and different changes in groups I. and II. The Group I. which had received thromboembolic prophylaxis did not develop deep venous thrombosis or pulmonary embolism, but the control group did. Based on their investigations, the authors concluded that they had been able to achieve F Xa inhibition by giving the above mentioned doses of Nadroparin Calcium which was enough to prevent thromboembolic complications in their model experiment of implanting hip endoprosthesis. [Journal Article; In English; Hungary]

CAS Registry Numbers: Anticoagulants; Fibrinolytic Agents; Nadroparin; 9001-26-7, Prothrombin; 9001-32-5, Fibrinogen; EC 3.4.21.6, ▲Factor Xa

Citation Subset Indicators: Index Medicus

MeSH Terms: Animals; Anticoagulants, administration & dosage (AD), * therapeutic use (TU); Arthroplasty, Replacement, Hip; Disease Models, Animal; Dogs; **Factor Xa**, antagonists & inhibitors (AI); Fibrinogen, analysis (AN); Fibrinolytic Agents, administration & dosage (AD), therapeutic use (TU); Follow-Up Studies; Injections, Subcutaneous; Nadroparin, administration & dosage (AD), * therapeutic use (TU); Partial Thromboplastin Time; Platelet Count, drug effects (DE); Premedication; Prothrombin, analysis (AN); Pulmonary Embolism, * **prevention** & control (PC); Thrombocytopenia, etiology (ET); Thrombophlebitis, * **prevention** & control (PC)

Acta Chirurgica Hungarica

Volume 36, Issue 1-4 , 1997, Pages 356-358

ISSN: 0231-4614

This Document

- Abstract-MEDLINE

External Links

- [Abstract + References in Scopus](#)
- [Cited By in Scopus](#)

Actions

- [Cited By](#)
- [Save as Citation Alert](#)
- [E-mail Article](#)
- [Export Citation](#)

[results list](#)

[previous](#)

381 of 596

[next](#) ▶

[Home](#) [Search](#) [Journals](#) [Books](#) [Abstract Databases](#) [My Profile](#) [Alerts](#)

Help

[Contact Us](#) | [Terms & Conditions](#) | [Privacy Policy](#)

Copyright © 2006 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.

Quick Search: within [All Full-text Sources](#) [Search Tips](#)[1 results list](#) [1 previous](#) **12 of 82** [next](#)**American Journal Of Cardiovascular Drugs: Drugs, Devices, And Other Interventions**

Volume 4, Issue 6, 2004, Pages 379-384

ISSN: 1175-3277

MEDLINE®

Clinical and experimental experience with factor Xa inhibitors

Viles-Gonzalez, Juan F; Gaztanaga, Juan; Zafar, Urooj M; Fuster, Valentin; Badimon, Juan J

Cardiovascular Biology Research Laboratory, Mount Sinai School of Medicine, Zena and Michael A. Wiener Cardiovascular Institute, New York, New York 10029, USA

This Document► [Abstract-MEDLINE](#)**External Links**

- [Abstract + References in Scopus](#)
- [Cited By in Scopus](#)

Actions

- [Cited By](#)
- [Save as Citation Alert](#)
- [E-mail Article](#)
- [Export Citation](#)

Abstract

Cardiovascular disease is the major cause of mortality in the industrial world today. We are constantly moving towards new and better ways of fighting this epidemic. Advances have been made in various fields such as patient education, imaging techniques, interventional cardiology, and novel therapeutic agents. In particular, antithrombotics are being studied with great interest and hope. Amid this class of agents, factor Xa inhibitors have already begun to show promising results in trials involving patients with acute coronary syndromes.

Whereas DX-9065a is in late stage clinical trials, fondaparinux sodium is available for clinical use. Promising results have been obtained with fondaparinux sodium in patients with coronary artery disease in the PENTUA (Pentasaccharide in Unstable Angina) and PENTALYSE (Pentasaccharide as an Adjunct to Fibrinolysis in ST-Elevation Acute Myocardial Infarction) trials. Besides having a direct effect on the coagulation cascade, they have shown properties that indirectly influence the remodeling of plaques in the coronary circulation. Available evidence on factor Xa inhibitors does not ensure a remedy to acute coronary syndromes but it gives hope of improving current treatments and reducing the morbidity and mortality of cardiovascular disease. The efficacy and tolerability of fondaparinux sodium in the prevention and treatment of deep vein thrombosis (with or without pulmonary embolism) has been established in several large trials such as PENTATHLON (Pentasaccharide in Total Hip Replacement Surgery), PENTAMAKS (Pentasaccharide in Major Knee Surgery), EPHESUS (European Pentasaccharide Hip

Elective Surgery), PENTHIFRA (Pentasaccharide in Hip-Fracture Surgery), and PENTHIFRA-Plus. Whereas fondaparinux sodium offers benefits over low molecular weight heparins and unfractionated heparin, the incidence of bleeding complications was greater with fondaparinux sodium than with unfractionated heparin. Treatment with factor VIIa can reverse the anticoagulant effect of fondaparinux sodium and this may be particularly important in patients who need to undergo emergency surgical procedures. Fondaparinux sodium has been recently approved for use, in conjunction with warfarin, in patients with symptomatic deep vein thrombosis or acute pulmonary embolism based on the results of two large trials conducted by the Matisse investigators. In conclusion, these observations strongly suggest the clinical potential of this class of agents in preventing arterial and venous thrombosis. [Journal Article, Review, Review, Tutorial; 37 Refs; In English; New Zealand]

CAS Registry Numbers: Anticoagulants; EC 3.4.21.6, [Factor Xa](#)

Citation Subset Indicators: Index Medicus

MeSH Terms: Anticoagulants, pharmacology (PD), * therapeutic use (TU); Coronary Arteriosclerosis, * drug therapy (DT); Dose-Response Relationship, Drug; [Factor Xa](#), * antagonists & inhibitors (AI); Humans; Randomized Controlled Trials; Venous Thrombosis, * prevention & control (PC)

American Journal Of Cardiovascular Drugs: Drugs, Devices, And Other Interventions

Volume 4, Issue 6 , 2004, Pages 379-384

ISSN: 1175-3277

[This Document](#)

► [Abstract-MEDLINE](#)

[External Links](#)



- [Abstract + References in Scopus](#)
- [Cited By in Scopus](#)

Actions

- [Cited By](#)
- [Save as Citation Alert](#)
- [E-mail Article](#)
- [Export Citation](#)

[results list](#)

[previous](#)

12 of 82

[next](#) ►

[Home](#) [Search](#) [Journals](#) [Books](#) [Abstract Databases](#) [My Profile](#) [Alerts](#)

Help


[Contact Us](#) | [Terms & Conditions](#) | [Privacy Policy](#)

Copyright © 2006 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.

NPL

		Results
12.	TITLE-ABSTR-KEY(factor xa) and TITLE-ABSTR-KEY(pulmonary embolous) [All Sources(- All Sciences -)]	0
11.	TITLE-ABSTR-KEY(factor xa) and TITLE-ABSTR-KEY(thrombotic complications) [All Sources(- All Sciences -)]	29
10.	TITLE-ABSTR-KEY(factor xa) and TITLE-ABSTR-KEY(venous thrombosis) [All Sources(- All Sciences -)]	312
9.	TITLE-ABSTR-KEY(factor xa) and TITLE-ABSTR-KEY(ischemia or ischemic) [All Sources(- All Sciences -)]	77
8.	TITLE-ABSTR-KEY(factor xa) and TITLE-ABSTR-KEY(stroke) [All Sources(- All Sciences -)]	49
7.	TITLE-ABSTR-KEY(factor xa) and TITLE-ABSTR-KEY(cerebrovascular) [All Sources(- All Sciences -)]	28
6.	TITLE-ABSTR-KEY(factor xa) and TITLE-ABSTR-KEY(angioplasty) [All Sources(- All Sciences -)]	71
5.	TITLE-ABSTR-KEY(factor xa) and TITLE-ABSTR-KEY(refractory angina) [All Sources(- All Sciences -)]	0
4.	TITLE-ABSTR-KEY(factor xa) and TITLE-ABSTR-KEY(unstable angina) [All Sources(- All Sciences -)]	49
3.	TITLE-ABSTR-KEY(factor xa) and TITLE-ABSTR-KEY(myocardial infarction) [All Sources(- All Sciences -)]	82
2.	TITLE-ABSTR-KEY(factor xa) and TITLE-ABSTR-KEY(prevention) [All Sources(- All Sciences -)]	596
1.	TITLE-ABSTR-KEY(factor xa) and TITLE-ABSTR-KEY(coronary) [All Sources(- All Sciences -)]	232

Copyright © 2006 Elsevier B.V. All rights reserved.
 ScienceDirect® is a registered trademark of Elsevier B.V.



chain nodes :

7 8 38 39 40 41 42 52

ring nodes :

1 2 3 4 5 6 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
28 29 30 31 32 33 43 44 45 46 47 48

chain bonds :

5-7 7-8 8-10 8-39 9-38 40-41 40-42

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-13 10-11 11-12 12-13 14-15 14-19 15-16 16-17
17-18 18-19 18-20 19-23 20-21 21-22 22-23 24-25 24-29 25-26 26-27 27-28 28-29
28-30 29-33 30-31 31-32 32-33 43-44 43-48 44-45 45-46 46-47 47-48

exact/norm bonds :

5-7 7-8 8-39 9-10 9-13 9-38 12-13 40-41 40-42

exact bonds :

8-10 10-11 11-12

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6 14-15 14-19 15-16 16-17 17-18 18-19 18-20 19-23 20-21
21-22 22-23 24-25 24-29 25-26 26-27 27-28 28-29 28-30 29-33 30-31 31-32 32-33
43-44 43-48 44-45 45-46 46-47 47-48

isolated ring systems :

containing 1 : 9 : 14 : 24 : 43 :

G1:[*1], [*2]

G2:[*3], [*4]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom
22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom
32:Atom 33:Atom 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:Atom 44:Atom
45:Atom

46:Atom 47:Atom 48:Atom 52:CLASS 53:CLASS

L1 STRUCTURE UPLOADED

=> d 11
L1 HAS NO ANSWERS
L1 STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam
SAMPLE SEARCH INITIATED 09:46:49 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 11 TO ITERATE

100.0% PROCESSED 11 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 22 TO 418
PROJECTED ANSWERS: 5 TO 234

L2 5 SEA SSS SAM L1

=> => s 11 sss ful
FULL SEARCH INITIATED 09:47:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 310 TO ITERATE

100.0% PROCESSED 310 ITERATIONS 129 ANSWERS
SEARCH TIME: 00.00.01


L3 129 SEA SSS FUL L1

=> => s 13
L4 8 L3

=> d 14 1-8 bib,ab,hitstr

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:153587 CAPLUS
 DN 140:368085
 TI 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa
 inhibitors. Part 3: Design, synthesis and SAR of orally bioavailable
 benzamidine-P4 inhibitors
 AU Jia, Zhaozhong J.; Wu, Yanhong; Huang, Wenrong; Zhang, Penglie; Song,
 Yonghong; Woolfrey, John; Sinha, Uma; Arfsten, Ann E.; Edwards, Susan T.;
 Hutchaleelaha, Athiwat; Hollennbach, Stanley J.; Lambing, Joseph L.;
 Scarborough, Robert M.; Zhu, Bing-Yan
 CS Millennium Pharmaceuticals, Inc., South San Francisco, CA, 94080, USA
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(5), 1229-1234
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 OS CASREACT 140:368085
 AB Using N,N-dialkylated benzamidines as the novel P4 motifs, we have
 designed and synthesized a class of 1-(2-naphthyl)-1H-pyrazole-5-
 carboxylamides as highly potent and selective fXa inhibitors with
 significantly improved hydrophilicity and in vitro anticoagulant activity.
 These benzamidine-P4 fXa inhibitors have displayed excellent oral
 bioavailability and long half-life.

IT **441327-92-0P**
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (preparation, anticoagulant effect and structure-activity relationship of
 orally bioavailable benzamidines as potent factor Xa inhibitors)
 RN 441327-92-0 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, N-[4-[(dimethylamino)iminomethyl]-2-
 fluorophenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




IT **330802-18-1P 684270-91-5P 684270-92-6P
 684270-93-7P 684270-94-8P 684270-95-9P
 684270-96-0P**
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation, anticoagulant effect and structure-activity relationship of orally bioavailable benzamidines as potent factor Xa inhibitors)


RN 330802-18-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-(aminoiminomethyl)-2-fluorophenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 684270-91-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2-fluoro-4-[imino(methylamino)methyl]phenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 684270-92-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-[(ethylmethylamino)iminomethyl]-2-fluorophenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 684270-93-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2-fluoro-4-[imino(methylpropylamino)methyl]phenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 684270-94-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2-fluoro-4-[imino[(2-methoxyethyl)methylamino)methyl]phenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 684270-95-9 CAPLUS

1H-Pyrazole-5-carboxamide, N-[4-[[[2-(dimethylamino)ethyl]methylamino]iminomethyl]-2-fluorophenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 684270-96-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2-fluoro-4-[imino[methyl(phenylmethyl)amino]methyl]phenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)



IT 330802-07-8 330802-67-0 330803-08-2


441328-10-5 441328-39-8 684270-90-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation, anticoagulant effect and structure-activity relationship of orally bioavailable benzamidines as potent factor Xa inhibitors)


RN 330802-07-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-[(dimethylamino)iminomethyl]phenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-67-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-[(dimethylamino)iminomethyl]-2-fluorophenyl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330803-08-2 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-chloro-2-naphthalenyl)-N-[4-[(dimethylamino)iminomethyl]-2-fluorophenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 441328-10-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-[(dimethylamino)iminomethyl]-2-fluorophenyl]-1-(3-fluoro-2-naphthalenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 441328-39-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-chloro-2-naphthalenyl)-N-[4-[(dimethylamino)iminomethyl]-2-fluorophenyl]-3-(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 684270-90-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[3-[(dimethylamino)iminomethyl]phenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2004:153586 CAPLUS
 DN 140:368084
 TI 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa
 inhibitors. Part 2: A survey of P4 motifs
 AU Jia, Zhaozhong J.; Wu, Yanhong; Huang, Wenrong; Zhang, Penglie; Clizbe,
 Lane A.; Goldman, Erick A.; Sinha, Uma; Arfsten, Ann E.; Edwards, Susan
 T.; Alphonso, Merlyn; Hutchaleelaha, Athiwat; Scarborough, Robert M.; Zhu,
 Bing-Yan
 CS Millennium Pharmaceuticals, Inc., South San Francisco, CA, 94080, USA
 SO Bioorganic & Medicinal Chemistry Letters (2004), 14(5), 1221-1227
 CODEN: BMCL8; ISSN: 0960-894X
 PB Elsevier Science B.V.
 DT Journal
 LA English
 AB A variety of P4 motifs have been examined to increase the binding affinity
 and in vitro anticoagulant potency of our biphenyl 1-(2-naphthyl)-1H-
 pyrazole-5-carboxylamide-based fXa inhibitors. Highly potent
 2-naphthyl-P1 fXa inhibitors ($K_i \leq 2$ nM) with improved in vitro
 anticoagulant activity ($2+TG \leq 1$ μ M) and respectable
 pharmacokinetic properties have been discovered.
 IT 330801-95-1 330802-45-4 330803-01-5
 330803-02-6 330803-03-7 441327-83-9
 441328-47-8 684233-55-4 684233-56-5
 684233-57-6 684233-58-7 684233-59-8
 684233-60-1
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa
 inhibitors)
 RN 330801-95-1 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-
 yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-45-4 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-
 yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330803-01-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-chloro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-02-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-1-(6-chloro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-03-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-chloro-2-naphthalenyl)-N-[3-fluoro-2'-(methylsulfonyl)][1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 441327-83-9 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[3-fluoro-2'-(methylsulfonyl)][1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 441328-47-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-chloro-2-naphthalenyl)-3-methyl-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 684233-55-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[3'-(aminomethyl)[1,1'-biphenyl]-4-yl]-1-(6-chloro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 684233-56-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[3'-(aminoiminomethyl)[1,1'-biphenyl]-4-yl]-1-(6-chloro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 684233-57-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-chloro-2-naphthalenyl)-N-[3'-(dimethylaminoiminomethyl)[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 684233-58-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-chloro-2-naphthalenyl)-N-[2'-(dimethylamino)iminomethyl][1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 684233-59-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminomethyl)[1,1'-biphenyl]-4-yl]-1-(6-chloro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 684233-60-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-chloro-2-naphthalenyl)-N-[2'-(dimethylamino)methyl][1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)



IT 441328-60-5 684233-61-2 684233-64-5


684233-67-8

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study)

(1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors)


RN 441328-60-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 684233-61-2 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-chloro-2-naphthalenyl)-N-[2'-(dimethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 684233-64-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(dimethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 684233-67-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(dimethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)

RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2003:432456 CAPLUS
 DN 139:390996
 TI Inhibition of Purified Factor Xa Amidolytic Activity May Not Be Predictive
 of Inhibition of In Vivo Thrombosis
 AU Sinha, Uma; Lin, Pei Hua; Edwards, Susan T.; Wong, Paul W.; Zhu, Bingyan;
 Scarborough, Robert M.; Su, Ting; Jia, Zhaozhong J.; Song, Yonghong;
 Zhang, Penglie; Clizbe, Lane; Park, Gary; Reed, Andrea; Hollenbach,
 Stanley J.; Malinowski, John; Arfsten, Ann E.
 CS Millennium Pharmaceuticals Inc, South San Francisco, CA, USA
 SO Arteriosclerosis, Thrombosis, and Vascular Biology (2003), 23(6),
 1098-1104
 CODEN: ATVBFA; ISSN: 1079-5642
 PB Lippincott Williams & Wilkins
 DT Journal
 LA English
 AB In this study we test the hypothesis that blood/plasma-based
 prothrombinase assays, rather than inhibition of purified factor Xa (fXa),
 are predictive of in vivo antithrombotic activity. Six fXa inhibitors
 with equivalent nanomolar Ki were studied in thrombin generation assays using
 human plasma/blood and endogenous macromol. substrate. In all assays,
 benzamidine inhibitors were more potent (100 to 800 nmol/L) than the
 aminoisoquinolines (5 to 58 μ mol/L) or neutral inhibitors (3 to 10
 μ mol/L). A similar rank order of compound inhibition was also seen in
 purified prothrombinase assays as well as in a rabbit model of deep vein
 thrombosis. Assays using prothrombinase with protein substrates are
 better predictors of in vivo efficacy than fXa Ki using amidolytic
 substrates.
 IT 330802-28-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (inhibition of purified factor Xa amidolytic activity may not be
 predictive of inhibition of in vivo thrombosis)
 RN 330802-28-3 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)-2-naphthalenyl]-N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX
 NAME)



RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD


L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:522631 CAPLUS
 DN 137:93747
 TI Preparation of pyrazolecarboxamides as inhibitors of factor Xa
 IN Zhu, Bing-yan; Jia, Zhaozhong Jon; Huang, Wenrong; Song, Yonghong; Kanter, James; Scarborough, Robert M.
 PA USA
 SO U.S. Pat. Appl. Publ., 303 pp., Cont.-in-part of U.S. Ser. No. 662,807.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 6

Appl

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002091116	A1	20020711	US 2001-794214	20010228
	US 6632815	B2	20031014		
	US 6720317	B1	20040413	US 2000-662807	20000915
	US 6686368	B1	20040203	US 2003-387927	20030312
	US 2004116399	A1	20040617	US 2003-600695	20030620
				<u> </u>	
PRAI	US 1999-154332P	P	19990917		
	US 2000-662807	A2	20000915		
	US 2001-794214	A1	20010228		


*W
ODP*

OS MARPAT 137:93747
 AB The title compds. AQDEGJX [A = alkyl, cycloalkyl, (un)substituted Ph, naphthyl, etc.; Q = a direct link, divalent alkyl, alkenyl, etc.; D = a direct link, (un)substituted Ph, 5-10 membered (non)aromatic heterocyclyl; E = a direct link, (CH₂)_qCO, CO(CH₂)_x, etc.; q, x = 0-2; G = (un)substituted Ph, 5-6 membered heteroaryl; J = a direct link, SO₂, CO, etc.; X = (un)substituted Ph, naphthyl, 6-membered heteroaryl, etc.] having activity against mammalian factor Xa, and useful in vitro or in vivo for preventing or treating coagulation disorders, were prepared E.g., a 3-step synthesis of the pyrazolecarboxamide I was given.
 IT 330802-00-1P 330802-43-2P 330802-51-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyrazolecarboxamides as inhibitors of factor Xa)
 RN 330802-00-1 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, N-(2'-cyano[1,1'-biphenyl]-4-yl)-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-43-2 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[5-[[[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]amino]carbonyl]-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 330802-51-2 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-(2'-cyano[1,1'-biphenyl]-4-yl)-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




IT	330801-92-8P	330801-94-0P	330801-95-1P
	330801-96-2P	330801-97-3P	330802-01-2P
	330802-02-3P	330802-03-4P	330802-07-8P
	330802-12-5P	330802-18-1P	330802-21-6P
	330802-22-7P	330802-23-8P	330802-24-9P
	330802-25-0P	330802-26-1P	330802-27-2P
	330802-28-3P	330802-29-4P	330802-30-7P
	330802-31-8P	330802-32-9P	330802-41-0P
	330802-42-1P	330802-44-3P	330802-45-4P
	330802-46-5P	330802-47-6P	330802-50-1P
	330802-52-3P	330802-53-4P	330802-54-5P
	330802-67-0P	330802-68-1P	330802-69-2P
	330802-70-5P	330802-71-6P	330802-72-7P
	330802-73-8P	330802-74-9P	330802-75-0P
	330802-98-7P	330802-99-8P	330803-00-4P
	330803-01-5P	330803-02-6P	330803-03-7P
	330803-08-2P	330803-09-3P	330803-10-6P
	330803-11-7P	330803-39-9P	441327-78-2P
	441327-79-3P	441327-80-6P	441327-81-7P
	441327-82-8P	441327-83-9P	441327-92-0P
	441327-93-1P	441327-94-2P	441327-95-3P
	441328-00-3P	441328-01-4P	441328-02-5P
	441328-04-7P	441328-05-8P	441328-06-9P
	441328-10-5P	441328-23-0P	441328-31-0P
	441328-32-1P	441328-33-2P	441328-35-4P
	441328-39-8P	441328-47-8P	441328-48-9P
	441328-49-0P	441328-50-3P	441328-51-4P
	441328-52-5P	441328-56-9P	441328-60-5P
	441328-61-6P	441328-65-0P	441328-66-1P
	441328-68-3P	441328-69-4P	441328-70-7P

441328-74-1b
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolecarboxamides as inhibitors of factor Xa)


BN 330801-92-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl-1-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 330801-94-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330801-95-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330801-96-2 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-chloro[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330801-97-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-bromo[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-01-2 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminomethyl)[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-02-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(3-fluoro-2-naphthalenyl)-3-methyl-N-[2'-(1-methylethyl)amino]methyl-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)




RN 330802-03-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(dimethylamino)methyl][1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-07-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-((dimethylamino)iminomethyl)phenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-12-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-(aminoiminomethyl)phenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-18-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-(aminoiminomethyl)-2-fluorophenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-21-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-(aminoiminomethyl)-2,5-difluorophenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-22-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-chloro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-23-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-bromo-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-24-9 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-hydroxy-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-25-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-cyano-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-26-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)-2-naphthalenyl]-N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-27-2 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-1-(3-cyano-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-28-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)-2-naphthalenyl]-N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-29-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-chloro[1,1'-biphenyl]-4-yl]-1-(3-cyano-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-30-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)-2-naphthalenyl]-N-[2'-(aminosulfonyl)-3-chloro[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-31-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-bromo[1,1'-biphenyl]-4-yl]-1-(3-cyano-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-32-9 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)-2-naphthalenyl]-N-[2'-(aminosulfonyl)-3-bromo[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)



RN 330802-41-0 CAPLUS


CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)-2-naphthalenyl]-N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-42-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)-2-naphthalenyl]-N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 330802-44-3 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[5-[[[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]amino]carbonyl]-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 330802-45-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-46-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-chloro[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-47-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-bromo[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-50-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 3-methyl-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-52-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminomethyl)[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-53-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(dimethylamino)methyl][1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-54-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[3'-(aminomethyl)[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-67-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-[(dimethylamino)iminomethyl]-2-fluorophenyl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-68-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-(aminoiminomethyl)-2-fluorophenyl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-69-2 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-methoxy-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-70-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-hydroxy-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-71-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-bromo-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-72-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-1-(6-bromo-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-73-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-chloro[1,1'-biphenyl]-4-yl]-1-(6-bromo-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-74-9 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-bromo[1,1'-biphenyl]-4-yl]-1-(6-bromo-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-75-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-5'-chloro[1,1'-biphenyl]-4-yl]-1-(6-bromo-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-98-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-(aminoiminomethyl)-2-fluorophenyl]-1-(6-bromo-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-99-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-bromo-2-naphthalenyl)-N-[2,5-difluoro-4-[imino(methylamino)methyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-00-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-bromo-2-naphthalenyl)-N-[2-chloro-4-[(dimethylamino)iminomethyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-01-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-chloro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-02-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-1-(6-chloro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-03-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-chloro-2-naphthalenyl)-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)



RN 330803-08-2 CAPLUS


CN 1H-Pyrazole-5-carboxamide, 1-(6-chloro-2-naphthalenyl)-N-[4-[(dimethylamino)iminomethyl]-2-fluorophenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-09-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)-2-naphthalenyl]-3-methyl- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 330803-10-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-[3-[(dimethylamino)iminomethyl]-2-naphthalenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-11-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-[3-(imino-1-pyrrolidinylmethyl)-2-naphthalenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-39-9 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 441327-78-2 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[5-[[[2'-(aminosulfonyl)-3-chloro[1,1'-biphenyl]-4-yl]amino]carbonyl]-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 441327-79-3 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[5-[[[2'-(aminosulfonyl)-3-bromo[1,1'-biphenyl]-4-yl]amino]carbonyl]-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 441327-80-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-[3-(hydroxymethyl)-2-naphthalenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 441327-81-7 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[5-[[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]amino]carbonyl]-3-methyl-1H-pyrazol-1-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441327-82-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(3-fluoro-2-naphthalenyl)-3-methyl-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 441327-83-9 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 441327-92-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-[(dimethylamino)iminomethyl]-2-fluorophenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 441327-93-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-[(dimethylamino)iminomethyl]-2,5-difluorophenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 441327-94-2 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2-chloro-4-[(dimethylamino)iminomethyl]phenyl]-1-[1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 441327-95-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[3-chloro-4-[(dimethylamino)iminomethyl]phenyl]-1-[1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 441328-00-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 441328-01-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 441328-02-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-chloro[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 441328-04-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(3-fluoro-2-naphthalenyl)-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 441328-05-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 441328-06-9 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-[(dimethylamino)iminomethyl]phenyl]-1-(3-fluoro-2-naphthalenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 441328-10-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-[(dimethylamino)iminomethyl]-2-fluorophenyl]-1-(3-fluoro-2-naphthalenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 441328-23-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-chloro-2-naphthalenyl)-N-[4-[(dimethylamino)iminomethyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 441328-31-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-chloro-2-naphthalenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 441328-32-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-1-(6-chloro-2-naphthalenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 441328-33-2 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-chloro[1,1'-biphenyl]-4-yl]-1-(6-chloro-2-naphthalenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 441328-35-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-chloro-2-naphthalenyl)-N-[4-[(dimethylamino)iminomethyl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 441328-39-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-chloro-2-naphthalenyl)-N-[4-[(dimethylamino)iminomethyl]-2-fluorophenyl]-3-(trifluoromethyl)- (9CI)
(CA INDEX NAME)




RN 441328-47-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-chloro-2-naphthalenyl)-3-methyl-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 441328-48-9 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 441328-49-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-1-(6-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 441328-50-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-fluoro-2-naphthalenyl)-3-methyl-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 441328-51-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 441328-52-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-[(dimethylamino)iminomethyl]phenyl]-1-(6-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 441328-56-9 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-[(dimethylamino)iminomethyl]-2-fluorophenyl]-1-(6-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 441328-60-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 441328-61-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-[(dimethylamino)iminomethyl]phenyl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 441328-65-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-[3-(aminosulfonyl)-2-naphthalenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 441328-66-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-1-[3-(aminosulfonyl)-2-naphthalenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 441328-68-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminosulfonyl)-2-naphthalenyl]-3-methyl-N-[2'-(methylsulfonyl)][1,1'-biphenyl]-4-yl]- (9CI) (CA INDEX NAME)




RN 441328-69-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminosulfonyl)-2-naphthalenyl]-N-[3-fluoro-2'-(methylsulfonyl)][1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 441328-70-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminosulfonyl)-2-naphthalenyl]-N-[4-[(dimethylamino)iminomethyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 441328-74-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminosulfonyl)-2-naphthalenyl]-N-[4-[(dimethylamino)iminomethyl]-2-fluorophenyl]-3-methyl- (9CI) (CA INDEX NAME)




IT 330803-42-4P 330803-47-9P 330803-57-1P
 330803-59-3P 330803-64-0P 330803-65-1P
 330803-67-3P 330803-70-8P 330803-72-0P
 330803-77-5P 330803-79-7P 330803-82-2P
 330803-87-7P 441330-08-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazolecarboxamides as inhibitors of factor Xa)


RN 330803-42-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-[[[(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-3-methyl-1-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 330803-47-9 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-[[[(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-57-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-2-naphthalenyl)-N-[2'-(3,5-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-59-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[3-chloro-2'-(3,5-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-1-(3-cyano-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-64-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)-2-naphthalenyl]-N-[2'-(1,1-dimethylethyl)amino]sulfonyl]-[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-65-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-2-naphthalenyl)-N-[2'-(1,1-dimethylethyl)amino]sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-67-3 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[5-[[2'-(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]amino]carbonyl]-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 330803-70-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330803-72-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(1,1-dimethylethyl)amino]sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330803-77-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(1,1-dimethylethyl)amino]sulfonyl]-1-(6-methoxy-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-79-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-1-(6-methoxy-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 330803-82-2 CAPLUS


CN 1H-Pyrazole-5-carboxamide, 1-(6-bromo-2-naphthalenyl)-N-[2'-(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-87-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)-2-naphthalenyl]-N-[2'-([(1,1-dimethyl-ethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 441330-08-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-[[(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-(trifluoromethyl)- (9CI)
(CA INDEX NAME)

L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:407969 CAPLUS
 DN 138:66142
 TI Design, synthesis and biological activity of novel non-amidine factor Xa inhibitors. Part 1: P1 structure-activity relationships of the substituted 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides
 AU Jia, Zhaozhong J.; Wu, Yanhong; Huang, Wenrong; Goldman, Erick; Zhang, Penglie; Woolfrey, John; Wong, Paul; Huang, Brian; Sinha, Uma; Park, Gary; Reed, Andrea; Scarborough, Robert M.; Zhu, Bing-Yan
 CS Medicinal Chemistry Department, Millennium Pharmaceuticals, Inc., South San Francisco, CA, 94080, USA
 SO Bioorganic & Medicinal Chemistry Letters (2002) 12(12), 1651-1655
 CODEN: BMCL8; ISSN: 0960-894X
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 OS CASREACT 138:66142
 AB Based on DuPont Pharmaceuticals' monobenzamidine lead structure SN429, we have designed the biphenyl 1-(2-naphthyl)-1H-pyrazole-5-carboxylamides as a novel series of non-basic factor Xa inhibitors. We have discovered that the displacement of the benzamidine moiety with substituted 2-naphthyl structures not only results in highly potent factor Xa inhibitors, but also significantly increases their enzyme specificity and oral bioavailability.
 IT 330801-92-8P 330802-25-0P 330802-26-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (design, synthesis and biol. activity of novel non-amidine factor Xa inhibitors)
 RN 330801-92-8 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl-1-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 330802-25-0 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-cyano-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 330802-26-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)-2-naphthalenyl]-N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)



IT 330801-94-0P 330802-23-8P 330802-24-9P

330802-41-0P 330802-43-2P 330802-69-2P

330802-70-5P 330802-71-6P 330803-01-5P

330803-09-3P 330803-10-6P 330803-39-9P

441327-80-6P 441327-81-7P 441328-00-3P


441328-31-0P 441328-65-0P 479499-82-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(design, synthesis and biol. activity of novel non-amidine factor Xa inhibitors)


RN 330801-94-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-23-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-bromo-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-24-9 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-hydroxy-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-41-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)-2-naphthalenyl]-N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-43-2 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[5-[[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]amino]carbonyl]-3-methyl-1H-pyrazol-1-yl- (9CI) (CA INDEX NAME)




RN 330802-69-2 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-methoxy-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-70-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-hydroxy-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-71-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-bromo-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 330803-01-5 CAPLUS


CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-chloro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-09-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)-2-naphthalenyl]-3-methyl- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 330803-10-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-[3-[(dimethylamino)iminomethyl]-2-naphthalenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-39-9 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 441327-80-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-[3-(hydroxymethyl)-2-naphthalenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 441327-81-7 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[5-[[[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]amino]carbonyl]-3-methyl-1H-pyrazol-1-yl]-, methyl ester (9CI) (CA INDEX NAME)




RN 441328-00-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 441328-31-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-chloro-2-naphthalenyl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 441328-65-0 CAPLUS


CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-[3-(aminosulfonyl)-2-naphthalenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 479499-82-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)-2-naphthalenyl]-N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




IT 330803-57-1P 479499-81-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(design, synthesis and biol. activity of novel non-amidine factor Xa inhibitors)


RN 330803-57-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-2-naphthalenyl)-N-[2'-(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)



RN 479499-81-5 CAPLUS


CN 2-Naphthalenecarboximidic acid, 3-[5-[[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]amino]carbonyl]-3-methyl-1H-pyrazol-1-yl]-, methyl ester (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:39605 CAPLUS
 DN 136:102380
 TI Preparation of novel guanidine mimics as factor Xa inhibitors
 IN Lam, Patrick Y.; Clark, Charles G.; Dominguez, Celia; Fevig, John M.; Han, Qi; Li, Renhua; Pinto, Donald J. P.; Pruitt, James R.; Quan, Mimi L.
 PA Dupont Pharmaceuticals Company, USA
 SO U.S., 117 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6339099	B1	20020115	US 1998-99358	19980618
	US 2002025963	A1	20020228	US 2001-924381	20010808
	US 6906070	B2	20050614		
	US 2003069258	A1	20030410	US 2002-98994	20020313
	US 6958356	B2	20051025		
	US 2004063772	A1	20040401	US 2003-602214	20030624
	US 6965036	B2	20051115		
PRAI	US 1997-50265P	P	19970620		
	US 1998-99358	A3	19980618		
	US 2001-924381	B1	20010808		
OS	MARPAT 136:102380				
AB	The title compds. [I; ring D = 5-membered aromatic system containing from 1-2 heteroatoms selected from N, O, S; ring D is substituted with 0-2 R groups; ring E contains 0-2 N atom and is substituted by 0-1 R groups; R = Cl, F, Br, I, OH, alkoxy, amino(alkyl), (alkyl)amino; Z = bond, alkylene, (CH ₂) _r O(CH ₂) _r , (CH ₂) _r NR ₃ (CH ₂) _r , (CH ₂) _r C(O)(CH ₂) _r , (CH ₂) _r C(O)O(CH ₂) _r , (CH ₂) _r OC(O)(CH ₂) _r , (CH ₂) _r C(O)NR ₃ (CH ₂) _r , etc. provided that Z does not form a N-N, N-O, N-S, NCH ₂ N, NCH ₂ O, or NCH ₂ S bond with ring M or group A; R _{1a-1b} = H, alk(en)yl, aminoalkyl, alkoxy, alternatively, R _{1a-1b} , when attached to adjacent carbon atoms, together with the atoms to which they are attached form a 5-8 membered (un)saturated ring (un)substituted and which contains from 0-2 heteroatoms selected from the group consisting of N, O, and S; alternatively, when Z is C(O)NH and R _{1a} is attached to a ring carbon adjacent to Z, then R _{1a} is a C(O) which replaces the amide hydrogen of Z to form a cyclic imide; R ₃ = H, alkyl, phenyl; A = (un)substituted carbocyclic, 5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, S; B = H, Y, X-Y; X = sulfonylalkyl, alkylsulfonyl, sulfonamide, etc.; Y = alkylamino, provided that X-Y does not form a N-N, O-N or S-N bond, carbocyclic group, 5-10 membered heterocyclic r = 0-3], inhibitors of factor Xa which are useful in treating and preventing a thromboembolic disorder, were prepared and formulated. Thus, a multi-step synthesis of the title compound II, starting with 7-aminoisoquinoline, was described. A number of compds. I were found to exhibit a Ki of ≤ 15 μM against factor Xa.				
IT	218299-04-8P				
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(preparation of novel guanidine mimics as factor Xa inhibitors)				
RN	218299-04-8 CAPLUS				
CN	1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)-2-naphthalenyl]-N-[2-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)				




IT 218302-16-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of novel guanidine mimics as factor Xa inhibitors)

RN 218302-16-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(azidomethyl)-2-naphthalenyl]-N-[2-fluoro-4-(methylsulfonyl)biphenyl-4-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 19

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:208248 CAPLUS

DN 134:252334

TI Preparation of 1-naphthyl-3-methyl-1H-pyrazole-5-carboxamides as
inhibitors of factor XaIN Zhu, Bing-Yan; Jia, Zhaozhong Jon; Huang, Wenrong; Song, Yonghong; Kanter, James; Scarborough, Robert M.

PA Cor Therapeutics Inc., USA

SO PCT Int. Appl., 314 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019798	A2	20010322	WO 2000-US25195	20000915
	WO 2001019798	A3	20011025		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2385589	AA	20010322	CA 2000-2385589	20000915
	AU 2000074866	A5	20010417	AU 2000-74866	20000915
	AU 781880	B2	20050616		
	EP 1216231	A2	20020626	EP 2000-963451	20000915
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000014078	A	20021231	BR 2000-14078	20000915
	TR 200201413	T2	20030221	TR 2002-200201413	20000915
	JP 2003509412	T2	20030311	JP 2001-523378	20000915
	NZ 517828	A	20031031	NZ 2000-517828	20000915
	NO 2002001230	A	20020521	NO 2002-1230	20020312
	ZA 2002002117	A	20031215	ZA 2002-2117	20020314
	ZA 2002002116	A	20040210	ZA 2002-2116	20020314
	ZA 2003006488	A	20040216	ZA 2003-6488	20030820
	ZA 2003006490	A	20040323	ZA 2003-6490	20030820
PRAI	US 1999-154332P	P	19990917	← Appl. Prov.	
	WO 2000-US25195	W	20000915		

OS MARPAT 134:252334

AB The title compds. AQDEGJX [A = alkyl, cycloalkyl, (un)substituted Ph; Q = a direct link, alkylene, CO, etc.; D = a direct link, (un)phenylene, etc.; E = a direct link, (CH₂)_qCO, SO₂, etc.; q = 0-2; G = (un)substituted Ph, (un)substituted 5-6 membered (non)aromatic heterocyclic a ring containing 1-4 heteroatoms selected from N, O and S; J = a direct link, SO₂, CO, etc.; X = (un)substituted Ph, naphthyl, heteroaryl] having activity against mammalian factor Xa, and therefore useful in vitro or in vivo for preventing or treating coagulation disorders, were prepared E.g., a 3-step synthesis of the pyrazolecarboxamide I was described.

IT 330802-00-1P 330802-51-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

Same Inv
Appl. PCT

(preparation of 1-naphthyl-3-methyl-1H-pyrazole-5-carboxamides as inhibitors of factor Xa)


RN 330802-00-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-(2'-cyano[1,1'-biphenyl]-4-yl)-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 330802-51-2 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-(2'-cyano[1,1'-biphenyl]-4-yl)-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




IT 330801-92-8P 330801-94-0P 330801-95-1P
 330801-96-2P 330801-97-3P 330802-01-2P
 330802-02-3P 330802-03-4P 330802-07-8P
 330802-12-5P 330802-18-1P 330802-21-6P
 330802-22-7P 330802-23-8P 330802-24-9P
 330802-25-0P 330802-26-1P 330802-27-2P
 330802-28-3P 330802-29-4P 330802-30-7P

330802-31-8P 330802-32-9P 330802-41-0P
 330802-42-1P 330802-43-2P 330802-44-3P
 330802-45-4P 330802-46-5P 330802-47-6P
 330802-50-1P 330802-52-3P 330802-53-4P
 330802-54-5P 330802-67-0P 330802-68-1P
 330802-69-2P 330802-70-5P 330802-71-6P
 330802-72-7P 330802-73-8P 330802-74-9P
 330802-75-0P 330802-98-7P 330802-99-8P
 330803-00-4P 330803-01-5P 330803-02-6P
 330803-03-7P 330803-08-2P 330803-09-3P
 330803-10-6P 330803-11-7P 330803-39-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 1-naphthyl-3-methyl-1H-pyrazole-5-carboxamides as inhibitors of factor Xa)


RN 330801-92-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl-1-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 330801-94-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330801-95-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330801-96-2 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-chloro[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330801-97-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-bromo[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-01-2 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminomethyl)[1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-02-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(3-fluoro-2-naphthalenyl)-3-methyl-N-[2'-(1-methylethyl)amino]methyl]-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)




RN 330802-03-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(dimethylamino)methyl]-[1,1'-biphenyl]-4-yl-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-07-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-[(dimethylamino)iminomethyl]phenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-12-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-(aminoiminomethyl)phenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-18-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-(aminoiminomethyl)-2-fluorophenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-21-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-(aminoiminomethyl)-2,5-difluorophenyl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-22-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-chloro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-23-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-bromo-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-24-9 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-hydroxy-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-25-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(3-cyano-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-26-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)-2-naphthalenyl]-N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-27-2 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-1-(3-cyano-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-28-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)-2-naphthalenyl]-N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-29-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-chloro[1,1'-biphenyl]-4-yl]-1-(3-cyano-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-30-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)-2-naphthalenyl]-N-[2'-(aminosulfonyl)-3-chloro[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-31-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-bromo[1,1'-biphenyl]-4-yl]-1-(3-cyano-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-32-9 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)-2-naphthalenyl]-N-[2'-(aminosulfonyl)-3-bromo[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)



RN 330802-41-0 CAPLUS


CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)-2-naphthalenyl]-N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-42-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminoiminomethyl)-2-naphthalenyl]-N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 330802-43-2 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[5-[[[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]amino]carbonyl]-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 330802-44-3 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[5-[[[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]amino]carbonyl]-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 330802-45-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-46-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-chloro[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-47-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-bromo[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-50-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 3-methyl-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-52-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminomethyl)[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-53-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(dimethylamino)methyl][1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-54-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[3'-(aminomethyl)[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-67-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-[(dimethylamino)iminomethyl]-2-fluorophenyl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-68-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-(aminoiminomethyl)-2-fluorophenyl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330802-69-2 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-methoxy-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-70-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-hydroxy-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-71-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-bromo-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-72-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-1-(6-bromo-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-73-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-chloro[1,1'-biphenyl]-4-yl]-1-(6-bromo-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-74-9 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-bromo[1,1'-biphenyl]-4-yl]-1-(6-bromo-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-75-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-5'-chloro[1,1'-biphenyl]-4-yl]-1-(6-bromo-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-98-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-(aminoiminomethyl)-2-fluorophenyl]-1-(6-bromo-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330802-99-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-bromo-2-naphthalenyl)-N-[2,5-difluoro-4-[imino(methylamino)methyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-00-4 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-bromo-2-naphthalenyl)-N-[2-chloro-4-[(dimethylamino)iminomethyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-01-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-(6-chloro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-02-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-1-(6-chloro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-03-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(6-chloro-2-naphthalenyl)-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)



RN 330803-08-2 CAPLUS


CN 1H-Pyrazole-5-carboxamide, 1-(6-chloro-2-naphthalenyl)-N-[4-[(dimethylamino)iminomethyl]-2-fluorophenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-09-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)-2-naphthalenyl]-3-methyl- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 330803-10-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-[3-[(dimethylamino)iminomethyl]-2-naphthalenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-11-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-1-[3-(imino-1-pyrrolidinylmethyl)-2-naphthalenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 330803-39-9 CAPLUS


CN 1H-Pyrazole-5-carboxamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)

IT **330803-99-1**

RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of 1-naphthyl-3-methyl-1H-pyrazole-5-carboxamides as inhibitors
 of factor Xa)

RN 330803-99-1 CAPLUS


CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminocarbonyl)-2-naphthalenyl]-N-[2'-
 [(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-3-methyl- (9CI)
 (CA INDEX NAME)

IT **330803-42-4P 330803-47-9P 330803-57-1P****330803-59-3P 330803-64-0P 330803-65-1P****330803-67-3P 330803-70-8P 330803-72-0P****330803-77-5P 330803-79-7P 330803-82-2P****330803-87-7P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of 1-naphthyl-3-methyl-1H-pyrazole-5-carboxamides as inhibitors)


of factor Xa)
 RN 330803-42-4 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, N-[2'-[[(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-3-methyl-1-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 330803-47-9 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, N-[2'-[[(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-1-(3-fluoro-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-57-1 CAPLUS
 CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-2-naphthalenyl)-N-[2'-[[(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-59-3 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[3-chloro-2'-[[[1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-1-(3-cyano-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-64-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)-2-naphthalenyl]-N-[2'-[[[1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-65-1 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-(3-cyano-2-naphthalenyl)-N-[2'-([(1,1-dimethylethyl)amino]sulfonyl]-3-fluoro[1,1'-biphenyl]-4-yl]-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 330803-67-3 CAPLUS

CN 2-Naphthalenecarboxylic acid, 3-[5-[[2'-([(1,1-dimethylethyl)amino]sulfonyl)[1,1'-biphenyl]-4-yl]amino]carbonyl]-3-methyl-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 330803-70-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(1,1-dimethyl-1-aminocarbonyl)ethyl]sulfonyl]-3-methyl-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330803-72-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(1,1-dimethyl-1-aminocarbonyl)ethyl]sulfonyl]-3-fluoro-1-[3-(methylsulfonyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 330803-77-5 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(1,1-dimethylaminosulfonyl)biphenyl]-4-yl]-1-(6-methoxy-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-79-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[2'-(1,1-dimethylaminosulfonyl)biphenyl]-4-yl]-1-(6-hydroxy-2-naphthalenyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 330803-82-2 CAPLUS


CN 1H-Pyrazole-5-carboxamide, 1-(6-bromo-2-naphthalenyl)-N-[2'-(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 330803-87-7 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)-2-naphthalenyl]-N-[2'-(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-3-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
 AN 1999:9833 CAPLUS
 DN 130:66494
 TI Preparation of novel guanidine mimics as factor Xa inhibitors
 IN Lam, Patrick Y.; Clark, Charles G.; Dominguez, Celia; Fevig, John Matthew;
 Han, Qi; Li, Renhua; Pinto, Donald Joseph-Phillip; Pruitt, James Russell;
 Quan, Mimi Lifen
 PA The Du Pont Merck Pharmaceutical Company, USA
 SO PCT Int. Appl., 268 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9857951	A1	19981223	WO 1998-US12680	19980618
	W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	ZA 9805247	A	19991217	ZA 1998-5247	19980617
	CA 2291442	AA	19981223	CA 1998-2291442	19980618
	AU 9879768	A1	19990104	AU 1998-79768	19980618
	AU 756755	B2	20030123		
	EP 991638	A1	20000412	EP 1998-930361	19980618
	EP 991638	B1	20050817		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	BR 9810137	A	20000808	BR 1998-10137	19980618
	EE 9900583	A	20000815	EE 1999-583	19980618
	EE 4153	B1	20031015		
	JP 2002505686	T2	20020219	JP 1999-504785	19980618
	NZ 502370	A	20021025	NZ 1998-502370	19980618
	AT 302198	E	20050915	AT 1998-930361	19980618
	ES 2244064	T3	20051201	ES 1998-930361	19980618
	TW 544453	B	20030801	TW 1998-87109910	19980819
	NO 9905965	A	19991203	NO 1999-5965	19991203
	NO 318359	B1	20050307		
	MX 9911908	A	20000531	MX 1999-11908	19991216
	LV 12496	B	20010120	LV 1999-178	19991216
	LT 4705	B	20000925	LT 1999-147	19991217
PRAI	US 1997-878884	A	19970619		
	WO 1998-US12680	W	19980618		
OS	MARPAT 130:66494				
AB	The title compds. [I; rings D-E represent guanidine mimics; ring D = CH2N:CH, CH2CH2N:CH, a 5-6 membered aromatic system containing 0-2 heteroatoms selected from the group N, O, and S; ring D is substituted with 0-2 R (substituents), provided that when ring D is unsubstituted, it contains at least one heteroatom; ring E contains 0-2 N atom and is substituted by 0-1 R; R = halo, OH, C1-3 alkoxy, etc.; M = (un)substituted pyrazole, imidazole, tetrazole, etc.], inhibitors of factor Xa which are useful in treating and preventing a thromboembolic disorder, were prepared and formulated. Thus, a multi-step synthesis of the title compound II, starting with 7-aminoisoquinoline, was described. A number of compds. I were found to exhibit a Ki of \leq 15 μ M against factor Xa.				
IT	218299-04-8P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);				

BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of novel guanidine mimics as factor Xa inhibitors)

RN 218299-04-8 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(aminomethyl)-2-naphthalenyl]-N-[2-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 218302-16-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of novel guanidine mimics as factor Xa inhibitors)

RN 218302-16-0 CAPLUS

CN 1H-Pyrazole-5-carboxamide, 1-[3-(azidomethyl)-2-naphthalenyl]-N-[2-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



=> => d his

(FILE 'HOME' ENTERED AT 09:45:57 ON 23 JAN 2006)

FILE 'REGISTRY' ENTERED AT 09:46:08 ON 23 JAN 2006

L1 STRUCTURE UPLOADED
L2 5 S L1 SSS SAM
L3 129 S L1 SSS FUL

FILE 'CAPLUS' ENTERED AT 09:47:32 ON 23 JAN 2006

L4 8 S L3

FILE 'CAOLD' ENTERED AT 09:48:10 ON 23 JAN 2006

=> s 13
L5 0 L3

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.44	209.37

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.00

STN INTERNATIONAL LOGOFF AT 09:48:22 ON 23 JAN 2006